Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis
Background A major cause of disability in secondary progressive multiple sclerosis (SPMS) is progressive brain atrophy, whose pathogenesis is not fully understood. The objective of this study was to identify protein biomarkers of brain atrophy in SPMS. Methods We used surface-enhanced laser desorption-ionization time-of-flight mass spectrometry to carry out an unbiased search for serum proteins...
متن کاملDefining secondary progressive multiple sclerosis.
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis,...
متن کاملImaging outcome measures for progressive multiple sclerosis trials
Imaging markers that are reliable, reproducible and sensitive to neurodegenerative changes in progressive multiple sclerosis (MS) can enhance the development of new medications with a neuroprotective mode-of-action. Accordingly, in recent years, a considerable number of imaging biomarkers have been included in phase 2 and 3 clinical trials in primary and secondary progressive MS. Brain lesion c...
متن کاملRegional Brain Atrophy in Multiple Sclerosis: increasing sensitivity to differences in relapsing-remitting and secondary-progressive disease
Introduction Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease, with relapsing-remitting (RR) and secondary-progressive (SP) subgroups considered as different phases in the progression of the disease. Pathologic and imaging studies suggest that the development of permanent neurologic impairment in MS is associated with progressive brain and spinal cord atrophy, and atrophy...
متن کاملSpinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
OBJECTIVES To measure the development of spinal cord (SC) atrophy over 1 year in patients with progressive multiple sclerosis (PMS) and determine the sample sizes required to demonstrate a reduction in spinal cord cross-sectional area (SC-CSA) as an outcome measure in clinical trials. METHODS In total, 44 PMS patients (26 primary progressive multiple sclerosis (PPMS), 18 secondary progressive...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2008
ISSN: 0028-3878,1526-632X
DOI: 10.1212/01.wnl.0000335765.55346.fc